Eleven papers published in July and August 2026 touch compounds this catalogue carries. They cluster into analytical work on matrix and stability, one manufacturing route, several results that reframe what a target protein does, and two that map the evidence base instead of adding to it.
- Eleven papers published in July and August 2026 touch compounds this catalogue carries.
- A Ghent University method paper found several compounds degraded in serum and plasma within a week at 4 and 22 degrees while staying detectable in dried matrices for two months.
- Benzyl alcohol esterified with a citric acid excipient during accelerated stability testing in a paper from Organon, forming isomeric monobenzyl-citrate esters.
- A UCLA scoping review found roughly two thirds of the literature on six widely marketed peptides is preclinical animal work, with a handful of heterogeneous human studies.
- In a four-arm rat study from Istanbul, a BPC-157 and TB-500 combination did not outperform either agent alone.
- Two candidate papers were cut because the publication record placed them in June rather than in the window this edition covers.
Eleven papers, two months
This is the first Research Watch. It covers what was published in July and August 2026 on compounds this catalogue carries, read against the standard set out in the charter: what the investigators did, in what system, what they measured, and what the work leaves unestablished.
Eleven papers made it. Two more were researched, written up, and then cut. Both had been logged as July or August work and the publication record put them in June. One was a study of a pentadecapeptide and nitric oxide signalling from the pharmacology department at the University of Zagreb, the other a biosynthesis paper from Warwick on a bacterial route to an NNMT inhibitor. Both are worth reading. Neither belongs in a column with two specific months in its title.
One affiliation needed correcting before a word was written. Shanghai Hongkou is a district of Shanghai, not Hong Kong, and that is the sort of error that survives forever once it has been copied twice.
The analytical papers, where the practical value sits
Two papers this window say more about handling than any amount of product copy does, and neither is really about a compound. Both are about the matrix it sits in.
The doping-control laboratory at Ghent University published a method in The Analyst in July covering 54 peptidic and non-peptidic compounds across dried blood spots, serum and plasma, using a single microextraction and high-resolution mass spectrometry. Detection limits landed between 0.05 and 1.25 nanograms per millilitre. Buried in the validation is the part worth keeping. In stored samples held at 4 and 22 degrees, several compounds degraded extensively in serum and plasma inside a week, while every compound in the panel stayed detectable in dried matrices across the full two-month study. The laboratory's stated motive was cheaper transport, since dried spots travel without refrigeration.
In August, analytical chemists at Organon reported in the Journal of Pharmaceutical and Biomedical Analysis what happened when a preservative stopped behaving like background. Two unexpected peaks appeared during accelerated stability testing of a topical hydrogel. LC-MS identified isomeric monobenzyl-citrate esters, and the team synthesised both and assigned them by benchtop NMR. The benzyl alcohol had esterified with citric acid, one of the formulation's own excipients.
Neither result transfers directly to anything in this catalogue. The habit of mind does. A stability figure describes a formulation held at stated conditions, not a property the molecule carries around with it.
One paper about making the molecule
Most published work on these compounds asks what they do. A paper in Applied Biochemistry and Biotechnology at the end of August asks how you make one.
A fermentation group at Tianjin University of Science and Technology integrated a BPC-157 coding sequence into the chromosome of Bacillus licheniformis 2709, expressed it as fusions with gamma-glutamyltranspeptidase and with the fluorescent protein mScarlet, and tuned the fermentation until the expression signal rose roughly threefold. Recovery was by ammonium sulfate precipitation. The validation step was a rodent assay, which is preclinical animal work and carries no implication for people.
The production question is the interesting one. Solid-phase synthesis is the default route for a fifteen-residue sequence, and a certificate assumes it throughout: the impurities a reader expects to see, the analytical panel that finds them, the way net peptide content is read. A microbial expression host changes all three. Host-cell protein carryover is a different problem from deletion sequences, and a certificate written for one route does not automatically describe the other.
Proteins doing more than the summary suggests
Three papers this window widen what a familiar target is understood to do, and all three cut against tidy mechanistic stories.
A group at the Center for Mitochondrial Medicine at UT Health San Antonio published in Cell Reports in August on prohibitin, described in this market almost entirely as a surface address on adipose vasculature. Running unbiased proteomics on MRS2, the channel carrying magnesium into mitochondria, they found the prohibitin complex among its main interacting partners. Hepatocytes lacking Phb1 took up markedly less mitochondrial magnesium, and loss-of-function and gain-of-function work pointed the same way, with no matching effect on calcium.
At the University of Louisiana Monroe, a pharmacology group reported in Experimental Eye Research in July on growth hormone-releasing hormone antagonists in a corneal endothelial cell model challenged with lipopolysaccharide. The readouts are barrier permeability, reactive oxygen species, and MAPK and STAT signalling. Nothing hormonal, in a tissue with no obvious growth-hormone story.
A review from Zhejiang Chinese Medical University in Frontiers in Cell and Developmental Biology worked through copper handling compartment by compartment. Lysyl oxidase cannot cross-link collagen until it has been copper-loaded through the ATP7A and ATP7B route in the trans-Golgi network, which makes the governing variable where copper arrives rather than how much is present. The authors are candid that direct evidence in bone cells for some of the organelle pathways they describe is still missing.
Results from systems nobody expected
Two papers reported findings in models chosen for reasons with nothing to do with this market, which is often where the more interesting evidence lives.
In the International Journal of Molecular Sciences in late July, researchers across the All-Russia Research Institute of Agricultural Biotechnology, Moscow State University and the Belozersky Institute grew tobacco in the presence of the tetrapeptide AEDL and its methylated analogue, then examined root cells by electron microscopy. Protein-storing vacuoles appeared where lytic vacuoles normally sit. One peptide produced starch-packed amyloplasts that control plants never showed, the other produced protein bodies and an autophagosome variant engulfing peroxisomes not previously described in tobacco. Gene expression data ran alongside the imaging.
Tobacco roots model nothing mammalian, and the value here is narrower. A four-residue peptide reached gene regulation in an unrelated organism, which turns a long-standing assertion into something testable.
Archives of Gerontology and Geriatrics carried a study in August from Fudan University on telomerase RNA component knockout mice across early and late generations. Serum iron and ferroportin fell, transferrin, ferritin and transferrin receptor expression rose in liver and lung, and hepcidin climbed as the deletion carried forward. Telomerase is usually discussed as a chromosome-end enzyme with a fairly contained job. This places it upstream of iron transport.
What the evidence base looks like from above
The two most useful papers of the window add no new data at all.
An orthopaedic group at UCLA published a scoping review in the American Journal of Sports Medicine in August covering six compounds that circulate constantly in this market. Working to PRISMA, screening in pairs with a third reviewer breaking ties, they reported the shape of the literature instead of extending it. Roughly two thirds of what they identified was preclinical animal work, most of it in rats. Human studies came to a handful, described as heterogeneous and short on rigorous controls. Their summary is that claimed benefits for musculoskeletal recovery and performance are unsubstantiated by current human trials.
That is a statement about the evidence rather than about the compounds, and the distinction matters. A thin clinical record is not the same finding as a compound tested and found wanting.
Second, from July, a group in Istanbul published a rat study in Joint Diseases and Related Surgery comparing BPC-157 alone, TB-500 alone, and the two combined in an Achilles tendon repair model. Thirty-two animals, four arms, read at four weeks with biomechanical testing alongside histology. The single-agent arms separated from control on several measures. The combination did not beat either agent on its own. The authors call the work exploratory and preclinical themselves, and one small rodent study settles nothing. It remains one of the few direct tests of the assumption every blend is sold on.
What is not in this edition
The silence is worth reporting too. Most families in this catalogue produced nothing at all in these two months, which is ordinary for compounds with small research communities and no commercial sponsor pushing a programme. A column that only ever reports activity gives a false impression of how much work is going on.
Nothing here is a new human trial. Of the eleven papers, one is an analytical method, one is formulation chemistry, one is a microbial expression route, three are cell or animal mechanism studies, one is plant biology, one is a knockout mouse model, one is a rat surgical model, and two are reviews of literature that already existed. The closest anything comes to human data is the scoping review, and what it reports is how little of that data there is.
That shape has held for years in this corner of the literature. It is the single most useful thing to know before reading any individual paper in it.
One from next door
Molecules published a review in August, from a group at Xi'an Jiaotong-Liverpool University, on orexin receptor antagonists and the sleep-wake system. It is here as a measuring stick rather than as news.
The orexin account has two named receptors, OX1R and OX2R, a functional split between them, and a class of molecules designed against that split. Mechanistic attention in sleep neurobiology has resolved to that level of specificity. Older peptide work on sleep never reached anything close to it, and the gap between a well-characterised receptor system and a compound with an uncertain mechanism is worth holding in view when reading either literature.
The next edition covers September. The sweep behind it runs at the end of the month rather than from memory.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Common questions
Why only eleven papers when the catalogue carries dozens of families?
Two of these are about mitochondria and tobacco roots. Why are they here?
Does the scoping review mean these compounds do not work?
Why publish a study that found no advantage for a product sold here?
How were the publication dates checked?
More laboratory guides
Sources
- Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. The Analyst doi:10.1039/d6an00455e. Ghent University doping-control laboratory; source of the matrix-dependent stability comparison and the detection limits quoted.
- Detection and structural elucidation of preservative-excipient isomeric esters of benzyl alcohol and citric acid in a topical hydrogel formulation. Journal of Pharmaceutical and Biomedical Analysis doi:10.1016/j.jpba.2026.117706. Organon; the preservative and excipient esterification found during accelerated stability testing.
- Efficient Expression of Small Molecule Bioactive Peptides in Bacillus licheniformis. Applied Biochemistry and Biotechnology doi:10.1007/s12010-026-05885-6. Tianjin University of Science and Technology; chromosomal integration, fusion expression and fermentation optimisation.
- Prohibitin controls MRS2-mediated mitochondrial Mg2+ uptake to shape bioenergetics. Cell Reports doi:10.1016/j.celrep.2026.117873. UT Health San Antonio; prohibitin as a regulator of mitochondrial magnesium transport.
- Growth hormone-releasing hormone antagonists protect endothelial corneal cells against lipopolysaccharides-induced inflammation. Experimental Eye Research doi:10.1016/j.exer.2026.111168. University of Louisiana Monroe; GHRH receptor pharmacology probed in a non-pituitary tissue.
- Copper Homeostasis and Organelle-Dependent Mechanisms in Bone Metabolism. Frontiers in Cell and Developmental Biology doi:10.3389/fcell.2026.1880910. Zhejiang Chinese Medical University; compartment-level account of copper delivery and lysyl oxidase loading.
- Structural Features of Root Cells of Nicotiana tabacum Grown in the Presence of Short Peptides AEDL and Its Methylated Analog AED(OMe)L. International Journal of Molecular Sciences doi:10.3390/ijms27156768. All-Russia Research Institute of Agricultural Biotechnology and Moscow State University; ultrastructural and gene expression changes in a plant model.
- Telomerase RNA component knockout is associated with iron accumulation and altered transferrin receptor 1 and ferroportin 1 expression in the liver and lung. Archives of Gerontology and Geriatrics doi:10.1016/j.archger.2026.106372. Fudan University; iron handling measured across knockout generations.
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American Journal of Sports Medicine doi:10.1177/03635465261464420. UCLA orthopaedics; PRISMA scoping review and the source of the proportion of the literature that is preclinical.
- Effects of BPC-157 and TB-500 on Achilles tendon healing in a rat model. Joint Diseases and Related Surgery doi:10.52312/jdrs.2026.2951. Four-arm rat study in which the combination did not outperform either single agent.
- Research Progress and Future Perspectives of Orexin Receptor Antagonists in Insomnia Therapy. Molecules doi:10.3390/molecules31162795. Xi'an Jiaotong-Liverpool University; included as a comparison of how far a mechanism can be resolved.
